Moore (1995) blames the FDA for letting encainide and flecainide onto the market.
The CAST study compared encainide and flecainide to a placebo and found excess deaths.
Impact of the Food and Drug Administration Approval of Flecainide and Encainide on Coronary Artery Disease Mortality: Putting Deadly Medicine to the Test.
Early review of the data by an independent safety monitoring board revealed that 56 of 730 patients given encainide or flecainide had died from some cause or suffered a heart attack, compared with 22 of 730 patients given placebo.
Other FDA-approved anti-arrhythmics exist but are more toxic than encainide and flecainide and have not been tested for their effects on mortality.
05 mL of 3 mg/L encainide (internal standard) and 1 mL of 0.
Diazepam and midazolam would increase the apparent concentration of encainide, the internal standard used in the assay for delavirdine, indinavir, nelfinavir, ritonavir, and saquinavir.
The mexdetine was discontinued, and he was subsequently placed on encainide, 25 mg every 8 hours, which resulted in a dramatic reduction in the number of premature ventricular contractions.
RELATIONSHIP OF SERUM PROTEIN CONCENTRATION TO ENCAINIDE THERAPY
The time course of the patient's encainide therapy, serum protein concentrations, and symptoms of edema are presented in Table 1.
Encainide was discontinued in this patient on May 4, 1988.
This case presents an interesting differential diagnosis for hypoproteinemia and mild pedal edema developing in a postmyocardial infarction patient receiving encainide.